Literature DB >> 26171066

Bioinformatics analysis of the target gene of fibroblast growth factor receptor 3 in bladder cancer and associated molecular mechanisms.

Xing Ai1, Zhuo-Min Jia2, Juan Wang3, Gui-Ping DI1, X U Zhang4, Fengling Sun1, Tong Zang1, Xiumei Liao1.   

Abstract

The aim of the present study was to elucidate the molecular mechanisms of fibroblast growth factor receptor 3 (FGFR3) activation via overexpression or mutation of the FGFR3 target gene in bladder cancer (BC). The transcription profile data GSE41035, which included 18 BC samples, containing 3 independent FGFR3 short hairpin (sh)RNA, and 6 control samples, containing enhanced green fluorescent protein (EGFP) shRNA, were obtained from the National Center of Biotechnology Information Gene Expression Omnibus database. The Limma package with multiple testing correction was used to identify differentially expressed genes (DEGs) between FGFR3 knockdown and control samples. Gene ontology (GO) and pathway enrichment analysis were conducted in order to investigate the DEGs at the functional level. In addition, differential co-expression analysis was employed to construct a gene co-expression network. A total of 196 DEGs were acquired, of which 101 were downregulated and 95 were upregulated. In addition, a gene signature was identified linking FGFR3 signaling with de novo sterol biosynthesis and metabolism using GO and pathway enrichment analysis. Furthermore, the present study demonstrated that the genes NME2, CCNB1 and H2AFZ were significantly associated with BC, as determined by the protein-protein interaction network of DEGs and co-expressed genes. In conclusion, the present study revealed the involvement of FGFR3 in the regulation of sterol biosynthesis and metabolism in the maintenance of BC; in addition, the present study provided a novel insight into the molecular mechanisms of FGFR3 in BC. These results may therefore contribute to the theoretical guidance into the detection and therapy of BC.

Entities:  

Keywords:  bladder cancer; differentially co-expressed genes; differentially expressed genes; gene ontology and pathway enrichment analysis; protein-protein interaction network

Year:  2015        PMID: 26171066      PMCID: PMC4487184          DOI: 10.3892/ol.2015.3231

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  45 in total

1.  Clinical spectrum of fibroblast growth factor receptor mutations.

Authors:  M R Passos-Bueno; W R Wilcox; E W Jabs; A L Sertié; L G Alonso; H Kitoh
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

Review 2.  Natural history of superficial bladder cancer. Prognostic features and long-term disease course.

Authors:  N M Heney
Journal:  Urol Clin North Am       Date:  1992-08       Impact factor: 2.241

3.  Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.

Authors:  C Billerey; D Chopin; M H Aubriot-Lorton; D Ricol; S Gil Diez de Medina; B Van Rhijn; M P Bralet; M A Lefrere-Belda; J B Lahaye; C C Abbou; J Bonaventure; E S Zafrani; T van der Kwast; J P Thiery; F Radvanyi
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

4.  FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.

Authors:  Xiangnan Du; Qian-Rena Wang; Emily Chan; Mark Merchant; Jinfeng Liu; Dorothy French; Avi Ashkenazi; Jing Qing
Journal:  Cancer Res       Date:  2012-09-26       Impact factor: 12.701

5.  FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

Authors:  Adel H Jebar; Carolyn D Hurst; Darren C Tomlinson; Colin Johnston; Claire F Taylor; Margaret A Knowles
Journal:  Oncogene       Date:  2005-08-04       Impact factor: 9.867

Review 6.  Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer.

Authors:  Arshad A Pandith; Zafar A Shah; Mushtaq A Siddiqi
Journal:  Urol Oncol       Date:  2010-09-06       Impact factor: 3.498

7.  DCGL: an R package for identifying differentially coexpressed genes and links from gene expression microarray data.

Authors:  Bao-Hong Liu; Hui Yu; Kang Tu; Chun Li; Yi-Xue Li; Yuan-Yuan Li
Journal:  Bioinformatics       Date:  2010-08-26       Impact factor: 6.937

8.  A gene expression ratio-based diagnostic test for bladder cancer.

Authors:  Lingsheng Dong; Andrew J Bard; William G Richards; Matthew D Nitz; Dan Theodorescu; Raphael Bueno; Gavin J Gordon
Journal:  Adv Appl Bioinform Chem       Date:  2009-01-12

9.  The present and future burden of urinary bladder cancer in the world.

Authors:  Martine Ploeg; Katja K H Aben; Lambertus A Kiemeney
Journal:  World J Urol       Date:  2009-02-15       Impact factor: 4.226

10.  Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

Authors:  D C Tomlinson; C D Hurst; M A Knowles
Journal:  Oncogene       Date:  2007-03-26       Impact factor: 9.867

View more
  6 in total

1.  Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3.

Authors:  Jie Luo; Bin Chen; Xian-Xiu Ji; Song-Wen Zhou; Di Zheng
Journal:  Tumour Biol       Date:  2015-08-28

Review 2.  Ontologies and Knowledge Graphs in Oncology Research.

Authors:  Marta Contreiras Silva; Patrícia Eugénio; Daniel Faria; Catia Pesquita
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

3.  Cantharidin alters the expression of genes associated with the NKG2D-associated immune response in TSGH-8301 human bladder carcinoma cells.

Authors:  Jehn-Hwa Kuo; An-Cheng Huang; Jen-Jyh Lin; Kuang-Chi Lai; Rick Sai-Chuen Wu; Jiun-Long Yang; Bin-Chuan Ji; Mei-Due Yang; Yung-Lin Chu; Jing-Gung Chung
Journal:  Oncol Lett       Date:  2017-05-12       Impact factor: 2.967

4.  Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer.

Authors:  Luca Falzone; Saverio Candido; Rossella Salemi; Maria S Basile; Aurora Scalisi; James A McCubrey; Francesco Torino; Salvatore S Signorelli; Maurizio Montella; Massimo Libra
Journal:  Oncotarget       Date:  2016-11-08

5.  Hepatic gene body hypermethylation is a shared epigenetic signature of murine longevity.

Authors:  Oliver Hahn; Thomas M Stubbs; Wolf Reik; Sebastian Grönke; Andreas Beyer; Linda Partridge
Journal:  PLoS Genet       Date:  2018-11-21       Impact factor: 5.917

6.  Bioinformatics Analysis Identified Key Molecular Changes in Bladder Cancer Development and Recurrence.

Authors:  Qingke Chen; Jieping Hu; Jun Deng; Bin Fu; Ju Guo
Journal:  Biomed Res Int       Date:  2019-11-16       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.